Bicycle Therapeutics (BCYC) CFO granted 58,000 stock options at $6.49

Rhea-AI Filing Summary

Bicycle Therapeutics reported that its Chief Financial Officer, Travis Thompson, received a grant of employee stock options on February 3, 2026. The award covers 58,000 options to buy ordinary shares at an exercise price of $6.49 per share.

The options were granted at no cost and are held directly. They vest over time: one-fourth of the total underlying shares vests on February 3, 2027, with the remaining options vesting in 36 equal monthly installments afterward, creating a multi-year retention and incentive structure.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Thompson Travis Alvin

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	58,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 58,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Travis Alvin

(Last) (First) (Middle)

C/O BICYCLE THERAPEUTICS PLC

BLOCKS A & B, PORTWAY BUILDING

(Street)

CAMBRIDGE X0 CB21 6GS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BICYCLE THERAPEUTICS PLC [ BCYC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$6.49	02/03/2026		A		58,000		(1)	02/03/2036	Ordinary Shares	58,000	$0	58,000	D

Explanation of Responses:

1. This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on February 3, 2027 and the remaining shares in 36 equal monthly installments thereafter.

	/s/ Travis Thompson	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bicycle Therapeutics (BCYC) report for its CFO?

Bicycle Therapeutics reported that its CFO, Travis Thompson, received a stock option grant on February 3, 2026. The award covers 58,000 employee stock options, providing the right to buy ordinary shares at a fixed exercise price over a multi-year vesting period.

How many stock options did the Bicycle Therapeutics (BCYC) CFO receive?

The CFO of Bicycle Therapeutics received 58,000 employee stock options. These options give him the right to purchase 58,000 ordinary shares at a preset exercise price, aligning his potential future gains with shareholder value over the long-term vesting schedule.

What is the exercise price of the Bicycle Therapeutics (BCYC) CFO’s options?

The employee stock options granted to the Bicycle Therapeutics CFO have an exercise price of $6.49 per share. This means he can, once vested, buy ordinary shares at $6.49 regardless of the market price at the time of exercise.

How do the Bicycle Therapeutics (BCYC) CFO stock options vest over time?

The CFO’s options vest gradually. One-fourth of the total underlying shares vests on February 3, 2027. The remaining three-fourths then vests in 36 equal monthly installments, creating a structured four-year vesting period to support executive retention.

Are the Bicycle Therapeutics (BCYC) CFO options held directly or indirectly?

The 58,000 employee stock options are reported as being held directly by the Bicycle Therapeutics CFO. The filing does not attribute them to any trust, partnership, or other related entity, indicating personal direct beneficial ownership of the derivative securities.

What type of security was granted to the Bicycle Therapeutics (BCYC) CFO?

The security granted is an employee stock option, described as a right to buy ordinary shares. This derivative security allows the CFO to purchase Bicycle Therapeutics ordinary shares at a fixed exercise price, subject to the detailed vesting schedule disclosed in the filing.